Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Clinical Pharmacology in Drug Development

Volumn 8, Issue 2, 2019, Pages 208-216

  Mohamed, Mohamed Eslam F ^a   Zeng, Jiewei ^a   Marroum, Patrick J ^a   Song, In Ho ^a   Othman, Ahmed A ^a  

^a ABBVIE INC   (United States)

Author keywords

ABT 494; extended release formulation; JAK1 inhibitors; pharmacokinetics; rheumatoid arthritis; upadacitinib

Indexed keywords

PLACEBO; UPADACITINIB; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FASTING; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM CONCENTRATION; MINIMUM CONCENTRATION; NORMAL HUMAN; PEAK-TROUGH FLUCTUATION; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STEADY STATE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; BIOAVAILABILITY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85045891247     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.462     Document Type: Article

References (15)

1. AbbVie. A study comparing ABT-494 to placebo in subjects with rheumatoid arthritis on a stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have an inadequate response to csDMARDs alone (SELECT-NEXT) [ClinicalTrials.gov identifier NCT02675426]. Accessed July 13, 2017.
2. AbbVie. A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to anti-TNF therapy (Celest Study) [ClinicalTrials.gov identifier NCT02365649]. Accessed July 13, 2017.
3. AbbVie. A study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis [ClinicalTrials.gov identifier NCT02819635]. Accessed July 13, 2017.
4. AbbVie. A study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis [ClinicalTrials.gov identifier NCT02925117]. Accessed July 13, 2017.
5. AbbVie. A study comparing ABT-494 to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (SELECT - PsA 1) [ClinicalTrials.gov identifier NCT03104400]. Accessed July 13, 2017.
6. AbbVie. A study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing spondylitis (SELECT Axis 1) [ClinicalTrials.gov Identifier NCT03178487]. Accessed July 13, 2017.
7. Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol. 2001;73(3):271–277.
8. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550.
9. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–1077.
10. Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558.
11. Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242–2248.
12. Klünder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57:977–988.
13. Kremer JM, Emery P, Camp HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–2877.
14. Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866.
15. Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; December 2002.